Cargando…
Uncontrolled severe T2 asthma: Which biological to choose? A biomarker-based approach
In recent years, advances in knowledge of molecular mechanisms involved in asthma have changed uncontrolled severe asthma (USA) treatment, with the appearance of biological treatment. USA is a heterogeneous entity with different endotypes and phenotypes. Nowadays, the biological drugs approved with...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9701749/ https://www.ncbi.nlm.nih.gov/pubmed/36452259 http://dx.doi.org/10.3389/falgy.2022.1007593 |
_version_ | 1784839605343748096 |
---|---|
author | López-Viña, Antolín Díaz Campos, Rocío M. Trisan Alonso, Andrea Melero Moreno, Carlos |
author_facet | López-Viña, Antolín Díaz Campos, Rocío M. Trisan Alonso, Andrea Melero Moreno, Carlos |
author_sort | López-Viña, Antolín |
collection | PubMed |
description | In recent years, advances in knowledge of molecular mechanisms involved in asthma have changed uncontrolled severe asthma (USA) treatment, with the appearance of biological treatment. USA is a heterogeneous entity with different endotypes and phenotypes. Nowadays, the biological drugs approved with asthma indication are omalizumab, mepolizumab, reslizumab, benralizumab and dupilumab. Tezepelumab is approved by the Food and Drug Administration (FDA) in the United States and, recently, by the European Medicines Agency (EMA). All these biological drugs have shown their efficacy in clinical trials, especially in reducing exacerbations, improving asthma control, quality of life, pulmonary function, and withdrawing systemic corticosteroids or at least reducing their daily dose, with some differences between them. Except for mepolizumab and reslizumab, biological drugs have different targets and thus different therapeutic indications should be expected; however, in some patients, more than one drug could be indicated, making the election more difficult. Because there are no direct comparisons between biological drugs, some biomarkers are used to choose between them, but they are not unbeatable. In this article, an algorithm to choose the first biological drug in a specific patient is proposed based on different study results and patient’ characteristics. |
format | Online Article Text |
id | pubmed-9701749 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-97017492022-11-29 Uncontrolled severe T2 asthma: Which biological to choose? A biomarker-based approach López-Viña, Antolín Díaz Campos, Rocío M. Trisan Alonso, Andrea Melero Moreno, Carlos Front Allergy Allergy In recent years, advances in knowledge of molecular mechanisms involved in asthma have changed uncontrolled severe asthma (USA) treatment, with the appearance of biological treatment. USA is a heterogeneous entity with different endotypes and phenotypes. Nowadays, the biological drugs approved with asthma indication are omalizumab, mepolizumab, reslizumab, benralizumab and dupilumab. Tezepelumab is approved by the Food and Drug Administration (FDA) in the United States and, recently, by the European Medicines Agency (EMA). All these biological drugs have shown their efficacy in clinical trials, especially in reducing exacerbations, improving asthma control, quality of life, pulmonary function, and withdrawing systemic corticosteroids or at least reducing their daily dose, with some differences between them. Except for mepolizumab and reslizumab, biological drugs have different targets and thus different therapeutic indications should be expected; however, in some patients, more than one drug could be indicated, making the election more difficult. Because there are no direct comparisons between biological drugs, some biomarkers are used to choose between them, but they are not unbeatable. In this article, an algorithm to choose the first biological drug in a specific patient is proposed based on different study results and patient’ characteristics. Frontiers Media S.A. 2022-11-14 /pmc/articles/PMC9701749/ /pubmed/36452259 http://dx.doi.org/10.3389/falgy.2022.1007593 Text en © 2022 López-Viña, Díaz Campos, Trisán Alonso and Melero Moreno. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY) (https://creativecommons.org/licenses/by/4.0/) . The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Allergy López-Viña, Antolín Díaz Campos, Rocío M. Trisan Alonso, Andrea Melero Moreno, Carlos Uncontrolled severe T2 asthma: Which biological to choose? A biomarker-based approach |
title | Uncontrolled severe T2 asthma: Which biological to choose? A biomarker-based approach |
title_full | Uncontrolled severe T2 asthma: Which biological to choose? A biomarker-based approach |
title_fullStr | Uncontrolled severe T2 asthma: Which biological to choose? A biomarker-based approach |
title_full_unstemmed | Uncontrolled severe T2 asthma: Which biological to choose? A biomarker-based approach |
title_short | Uncontrolled severe T2 asthma: Which biological to choose? A biomarker-based approach |
title_sort | uncontrolled severe t2 asthma: which biological to choose? a biomarker-based approach |
topic | Allergy |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9701749/ https://www.ncbi.nlm.nih.gov/pubmed/36452259 http://dx.doi.org/10.3389/falgy.2022.1007593 |
work_keys_str_mv | AT lopezvinaantolin uncontrolledseveret2asthmawhichbiologicaltochooseabiomarkerbasedapproach AT diazcamposrociom uncontrolledseveret2asthmawhichbiologicaltochooseabiomarkerbasedapproach AT trisanalonsoandrea uncontrolledseveret2asthmawhichbiologicaltochooseabiomarkerbasedapproach AT meleromorenocarlos uncontrolledseveret2asthmawhichbiologicaltochooseabiomarkerbasedapproach |